Europeiska unionen - svenska - EMA (European Medicines Agency)

gilead sciences ireland uc - idelalisib - lymphoma, non-hodgkin; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, other antineoplastic agents - zydelig is indicated in combination with an anti‑cd20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (cll):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or tp53 mutation in patients who are not eligible for any other therapies. zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (fl) that is refractory to two prior lines of treatment.

Europeiska unionen - svenska - EMA (European Medicines Agency)

instituto grifols s.a. - fostamatinib dinatrium - trombocytopeni - andra systemiska hemostatika - tavlesse är indicerat för behandling av kronisk immun trombocytopeni (itp) hos vuxna patienter som är refraktära mot andra behandlingar.

Europeiska unionen - svenska - EMA (European Medicines Agency)

dynavax gmbh - hepatit b-ytantigen - hepatit b - vacciner - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

sun pharmaceutical industries europe b.v. - ganirelixacetat - injektionsvätska, lösning i förfylld spruta - 0,25 mg/0,5 ml - ganirelixacetat 0,27 mg aktiv substans; mannitol hjälpämne - ganirelix

Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis europharm ltd. - amlodipin, valsartan, hydroklortiazid - hypertension - angiotensin ii-antagonister, vanligt, angiotensin ii-antagonister, kombinationer - behandling av essentiell hypertoni som substitutionsterapi hos vuxna patienter vars blodtryck är adekvat kontrollerad på kombinationen av amlodipin, valsartan och hydroklortiazid (hct), tas antingen som tre single-komponent formuleringar eller som en dual-komponent och en single-komponent formulering.

Europeiska unionen - svenska - EMA (European Medicines Agency)

novartis europharm limited - nepafenak - pain, postoperative; ophthalmologic surgical procedures - ögonsjukdomar - nevanac is indicated for: , prevention and treatment of postoperative pain and inflammation associated with cataract surgery;, reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients.

Europeiska unionen - svenska - EMA (European Medicines Agency)

allergan pharmaceuticals international limited - eluxadoline - irritable bowel syndrome; diarrhea - antidiarrheals, tarm -, antiinflammatoriska / antiinfective agenter - truberzi är indicerat hos vuxna för behandling av irritabelt tarmsyndrom med diarré (ibs d).

Europeiska unionen - svenska - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artrit, reumatoid - immunsuppressiva - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 och 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orifarm ab - ganirelixacetat - injektionsvätska, lösning i förfylld spruta - 0,25 mg/0,5 ml - mannitol hjälpämne; ganirelixacetat 0,27 mg aktiv substans

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

orifarm generics a/s - ganirelixacetat - injektionsvätska, lösning i förfylld spruta - 0,25 mg/0,5 ml - mannitol hjälpämne; ganirelixacetat 0,27 mg aktiv substans